Neurodegenerative Disease Drugs Market Report (2022 to 2030) – Novartis AG, Sanofi S.A., Pfizer Inc., Biogen Inc., Merck & CO. Inc., F. Hoffman-La Roche Ltd

Pune, Oct. 10, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global neurodegenerative disease drugs market is expected to clock US$ 77.01 Billion by 2030 and to grow at a CAGR of 6.8% during the forecast period. Supported by the increasing research and development on drug commercialization. This exclusive information is published by Growth Plus Reports in its report titled “Neurodegenerative Disease Drugs Market – Global Outlook & Forecast 2022-2030”

The global neurodegenerative disease drugs market has been analyzed from four perspectives: drug class, disease indication, route of administration, and region.

Get a Sample Copy of the Research Report: https://growthplusreports.com/inquiry/request-sample/neurodegenerative-disease-drugs-market/7838

Market Driver

Major drivers increasing the growth of neurodegenerative disease drugs market are rising research and development in treatment and diagnosis procedures. Investigation into the origins of neurodegenerative diseases and potential cures is recently rising. In preclinical or clinical trials, a number of treatments are being assessed, including cell therapies, oligonucleotides, and monoclonal antibodies. These initiatives hold a promise for the prevention, delayed progression, and eventual treatment of neurological disorders.

Excerpts from ‘By Drug Class’

According to drug class, global market is categorized into:

• Immunomodulators
• Dopamine Agonists
• Interferons
• Decarboxylase Inhibitors

Medication known as immunomodulators can improve immune function by altering the immune system response. By concentrating exclusively on specific immune system components, immunomodulators are more selective in their effectiveness and reduce the risk of adverse effects from immunological dysfunction. Interferons help the immune system identify and eliminate infected cells. They can stop the development and spread of infectious cells as well as protect other cells from getting infected. Parkinson’s disease is usually treated with dopamine agonists (DA), which delay the administration of levodopa medication and reduce unpleasant motor fluctuations.

Excerpts from ‘By Disease Indication’

Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and others comprise the segments of the global market for neurodegenerative disease drugs. In terms of disease indications, the Alzheimer’s disease category has dominated the market. Alzheimer’s disease causes the brain cells to degenerate, which leads to cell death and degeneration. Dementia, which is characterized by a continuous deterioration in mental, behavioral, and social capacities and reduces a person’s ability to operate independently, is primarily brought on by Parkinson’s disease. Spinal muscular atrophy (SMA) is a hereditary disorder that affects the brain, the peripheral nervous system, and voluntary muscle movement (skeletal muscle). Rising prevalence of diseases is anticipated to increase research and development procedures for drug development.

Speak to our Analyst to Understand the Impact of COVID-19 on Your Business: https://growthplusreports.com/inquiry/speak-analyst/neurodegenerative-disease-drugs-market/7838

Excerpts from ‘By Region’

Excerpts from ‘Competitive Landscape’

Some of the prominent players operating in the global neurodegenerative disease drugs market are:

• Novartis AG
• Sanofi S.A
• Orion Pharma Ltd
• F. Hoffman-La Roche Ltd
• Teva Pharmaceuticals Industries Inc
• ACADIA Pharmaceuticals Inc
• Merck & CO. Inc
• Pfizer Inc
• H. Lundbeck A/S
• Biogen Inc
• UCB S.A
• Boehringer Ingelheim International GmbH

Table of Content

1. INTRODUCTION
   1. Market Ecosystem 
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2031
2. Currency Used in the Report
3. RESEARCH METHODOLOGY 
   1.    Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       
4. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021) 
5. MARKET DYNAMICS
   1. Drivers
   2. Restraints
   3. Opportunities
6. GLOBAL NEURODEGENERATIVE DISEASE DRUGS MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
   1. Immunomodulators
   2. Dopamine Agonists
   3. Interferons
   4. Decarboxylase Inhibitors
   5. Others
7. GLOBAL NEURODEGENERATIVE DISEASE DRUGS MARKET – ANALYSIS & FORECAST, BY DISEASE INDICATION
   1. Parkinson’s Disease
   2. Multiple Sclerosis
   3. Alzheimer’s Disease
   4. Spinal Muscular Atrophy
   5. Others
8. GLOBAL NEURODEGENERATIVE DISEASE DRUGS MARKET – ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL 
   1. Injection
   2. Oral 
   3. Transdermal 

TOC Continued…

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Directly Purchase a Premium Copy of Neurodegenerative Disease Drugs Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=LLZw7qyh1Lya00VDVXTNooVpxjig7IKwyVdpAL6e&report_id=7838&license=Single

About Us:

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.